Sagetis Biotech announces the appointment of Dr. Manuel Hidalgo as a member of its Scientific Advisory Board

July 19, 2017

Barcelona, July 19 2017 - Sagetis Biotech, a pioneer in the development of innovative coated virotherapies for treatment of cancer, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of Dr. Manuel Hidalgo.

 

Dr. Hidalgo is an internationally renowned oncologist in the treatment of pancreatic cancer. Currently, he serves as Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center in Boston where he is also Co-Director of the Pancreatic Cancer Research Program. Dr. Hidalgo is also Professor of Medicine at the Harvard Medical School. His ground-breaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer. This encompasses the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.

 

His most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalized medicine in Pancreatic Ductal Adenocarcinoma (PDAC). About 15 years ago he initiated the development of patient derived xenograft models of pancreas cancer as a platform for translational studies in this disease. Dr. Hidalgo has been the recipient of a European Research Council advanced grant.

 

“We are very pleased to welcome Dr. Hidalgo as member of Sagetis’ Advisory Board” said Eduard Diviu, Chief Executive Officer of Sagetis Biotech. “Dr. Hidalgo’s experience as a key opinion leader (KOL) in the field of pancreatic cancer and his proven track record in clinical development of anticancer agents will be of great value for us as we are progressing towards clinical testing of our lead product SAG-101 in pancreatic cancer patients”.

 

Dr. Manuel Hidalgo will join existing members of Sagetis SAB: Dr. Cristina Fillat, Gene Therapy and Cancer Principal Investigator at IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Dr. Ramon Alemany, Head researcher at the gene and viral cancer therapy at Institut Català d’Oncologia (ICO)-Idibell and an internationally recognized expert in oncolytic adenoviruses for cancer treatment, Prof. Salvador Borrós, Co-founder, member of the Board at Sagetis Biotech and Full Professor at IQS and Dr. Robert Elfont, John-Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology.

 

 

About Sagetis Biotech

 

Sagetis Biotech is devoted to developing an innovative polymeric technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors.

 

Privately funded and based in Barcelona, Sagetis Biotech is developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR RETROVIRAL AND PLASMID-BASED APPLICATIONS

March 29, 2019

1/4
Please reload

Recent Posts
Please reload

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy